2013-09-15 17:53:34 - New Pharmaceuticals market report from Global Markets Direct: "Obesity - Pipeline Review, H2 2013"
Global Markets Direct's, 'Obesity - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Obesity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Obesity. Obesity - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Full Report Details at
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for
the indicated disease.
* A snapshot of the global therapeutic scenario for Obesity.
* A review of the Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Obesity pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.
Reasons to Get this Report
* Identify and understand important and diverse types of therapeutics under development for Obesity.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Companies Mentioned in this Report: Boehringer Ingelheim GmbH, Shionogi & Co., Ltd., Amgen Inc., Sanofi-Aventis, AstraZeneca PLC, Eli Lilly and Company, Athersys, Inc., GlaxoSmithKline plc, Isis Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Plexxikon Inc., BioLineRx, Ltd., Ipsen S.A., Chong Kun Dang Pharmaceutical, Glenmark Pharmaceuticals Ltd., GTx, Inc., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Norgine Limited, Pfizer Inc., VIVUS, Inc., Zydus Cadila Healthcare Limited, Genfit, Arrowhead Research Corporation, Ligand Pharmaceuticals Incorporated, Calzada Limited, PROLOR Biotech, Inc., NeuroSearch A/S, Orchid Chemicals & Pharmaceuticals Ltd, Corcept Therapeutics Incorporated, Arena Pharmaceuticals, Inc., WhanIn Pharmaceutical Co., Ltd., Unigene Laboratories, Inc., Theratechnologies Inc., Bukwang Pharmaceutical Co., Ltd., LG Life Sciences, Ltd, Transition Therapeutics Inc., Suven Life Sciences Ltd., Phynova Group Ltd, Orexigen Therapeutics, Inc., DiaMedica Inc., NeuroVive Pharmaceutical AB, Digna Biotech, S.L., Betagenon AB, Sirtris Pharmaceuticals, Inc., Jenrin Discovery, Inc., Upsher-Smith Laboratories, Inc., Metabolex, Inc, Helsinn Healthcare S.A., Xenon Pharmaceuticals Inc., Spherix Incorporated, Ocera Therapeutics, Inc., Aileron Therapeutics, Inc., AngioChem Inc., Global Health Ventures Inc., Zafgen Inc., Ambrx, Inc., Braasch Biotech LLC, Zealand Pharma A/S, Indus Biotech Private Limited, Intarcia Therapeutics, Inc., Thrasos, Inc., Versartis, Inc., Kainos Medicine, Inc., Avaxia Biologics, Inc., Omeros Corporation, Aegis Therapeutics, LLC, BRIDGE BIORESEARCH PLC, Globeimmune, Inc., Targacept, Inc., Molecular Design International, Inc., N-Gene Research Laboratories, Inc., PepTcell Limited, Galenea Corp., Verva Pharmaceuticals Limited, Regulus Therapeutics Inc., Esperion Therapeutics, Inc., Domainex Ltd., Lithera, Inc., DiscoveryBiomed, Inc., GlaxoSmithKline Inc., Motif BioSciences, Inc., Sirona Biochem Corp, Vicore Pharma AB, Reviva Pharmaceuticals Inc., PharmaIN Corporation, Rhythm Pharmaceuticals
About Global Markets Direct
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.